Quinsam Announces Q1/2026 Results
Toronto, Ontario--(Newsfile Corp. - May 19, 2026) - Quinsam Capital Corporation (CSE: QCA) ("Quinsam" or the "Company") is announcing its Q1/2026 results, with net income of $1.4 million ($0.015 per share basic, $0.015 fully diluted) versus net income of $0.2 million ($0.002 per share basic, $0.002 fully diluted) in Q1/2025. Investors can acces
Services bancaires / financiers, Cannabis, Cultivateurs de cannabis, Fournisseurs de services auxiliaires liés au cannabis
2026-05-19 8:00 AM EDT | Quinsam Capital Corporation
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechanism Research
Toronto, Ontario--(Newsfile Corp. - May 14, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-05-14 8:30 AM EDT | Rhelion Life Sciences Corp.
Red Light Holland Announces Shareholder Approval of Name Change and Announces Voting Results from 2026 Annual General and Special Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light Holland" or the "Company") is pleased to announce that shareholders overwhelmingly approved the Company's proposed corporate name change at the Company's annual general and special meeting of shareholders ("Shareholders") held on Monday, May 11, 2026 at the Company's office in Toronto (the "Meeting"). The special resolution approving t
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-05-13 9:12 AM EDT | Rhelion Life Sciences Corp.
Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intellectual Property
Peer-reviewed results published yesterday (May 7, 2026) in JAMA Network Open demonstrate that a single dose of psilocybin meaningfully reduced cocaine use in adults with cocaine use disorder over six months, with no serious adverse events Filament Health Corp., a wholly-owned subsidiary of Red Light Holland, holds the exclusive worldwide license to the trial data and certain associated intellectual property, with the goal of supporting future regulatory authoriza
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-05-08 7:30 AM EDT | Rhelion Life Sciences Corp.
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions
Toronto, Ontario--(Newsfile Corp. - May 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-05-07 7:30 AM EDT | Rhelion Life Sciences Corp.
Red Light Holland Announces Intention to Rebrand
New name and branding to be announced in the coming weeks, better aligned with the Company's scientific mandate and all business segments Name change resolution to be voted on by shareholders at the upcoming Annual General and Special Meeting ("AGSM") on May 11, 2026 Company urges all shareholders to vote IN FAVOUR of the name change resolution to support the rebranding exercise Rebranding reflects the combined focus on clinical research, GMP
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-05-04 8:30 AM EDT | Rhelion Life Sciences Corp.
Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution
Establishes a vertically integrated platform spanning pharmaceutical-grade botanical drug development and global consumer distribution Adds Filament's extensive intellectual property portfolio, including 70+ patents and proprietary extraction technologies Leverages Health Canada Dealer's License and FDA-aligned clinical development pathways, including IND-enabled activities Positions the Company at the forefront of the rapidly emerging regu
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-30 7:30 AM EDT | Rhelion Life Sciences Corp.
Red Light Holland Announces Filament Health Obtains Final Order for Proposed Arrangement
Toronto, Ontario--(Newsfile Corp. - April 29, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to announce that, further to their joint press release dated March 10, 2026, March 23, 2026 and April 27, 2026, that the Supreme Court of British Columbia has issued a final order (the "Final Order") approving the previously announced acquisition by Red Ligh
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-29 7:30 AM EDT | Rhelion Life Sciences Corp.